ATE245991T1 - Behandlung chronischer entzündungskrankheiten mit cm101/gbs-toxin - Google Patents

Behandlung chronischer entzündungskrankheiten mit cm101/gbs-toxin

Info

Publication number
ATE245991T1
ATE245991T1 AT98904796T AT98904796T ATE245991T1 AT E245991 T1 ATE245991 T1 AT E245991T1 AT 98904796 T AT98904796 T AT 98904796T AT 98904796 T AT98904796 T AT 98904796T AT E245991 T1 ATE245991 T1 AT E245991T1
Authority
AT
Austria
Prior art keywords
chronic inflammatory
treatment
inflammatory diseases
gbs toxin
toxin
Prior art date
Application number
AT98904796T
Other languages
English (en)
Inventor
Carl G Hellerqvist
Barbara D Wamil
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Application granted granted Critical
Publication of ATE245991T1 publication Critical patent/ATE245991T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT98904796T 1997-01-29 1998-01-29 Behandlung chronischer entzündungskrankheiten mit cm101/gbs-toxin ATE245991T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/790,989 US6028060A (en) 1997-01-29 1997-01-29 Treatment of chronic inflammatory diseases with CM101/GBS toxin
PCT/US1998/001852 WO1998032452A1 (en) 1997-01-29 1998-01-29 Treatment of chronic inflammatory diseases with cm101/gbs toxin

Publications (1)

Publication Number Publication Date
ATE245991T1 true ATE245991T1 (de) 2003-08-15

Family

ID=25152333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904796T ATE245991T1 (de) 1997-01-29 1998-01-29 Behandlung chronischer entzündungskrankheiten mit cm101/gbs-toxin

Country Status (11)

Country Link
US (2) US6028060A (de)
EP (1) EP0981355B1 (de)
JP (1) JP2001509797A (de)
CN (1) CN1292759C (de)
AT (1) ATE245991T1 (de)
AU (1) AU6258898A (de)
DE (1) DE69816807T2 (de)
DK (1) DK0981355T3 (de)
ES (1) ES2205450T3 (de)
PT (1) PT981355E (de)
WO (1) WO1998032452A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028060A (en) * 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
US6803448B1 (en) 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
US8609614B2 (en) 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
CA3255684A1 (en) 2010-07-26 2025-05-23 Qu Biologics Inc. Immunogenic anti-inflammatory compositions
CN113855791B (zh) 2014-05-02 2024-11-19 Qu生物制药公司 抗微生物免疫调节
EP3487874A1 (de) 2016-07-20 2019-05-29 Westfälische Wilhelms-Universität Münster Komplexspezifische standardisierung von immunologischen verfahren zur quantifizierung von s100a12

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS557014A (en) * 1978-06-29 1980-01-18 Chugai Pharmaceut Co Ltd Antitumor agent and its preparation
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
US4895838A (en) * 1988-03-09 1990-01-23 Trustees Of Boston University Method for provoking angiogenesis by administration of angiogenically active oligosaccharides
US5010062A (en) * 1989-09-25 1991-04-23 Vanderbilt University Therapeutic agent and method of inhibiting vascularization of tumors
US5225331A (en) * 1991-04-25 1993-07-06 National Research Council Of Canada Immunoassay for detecting group b streptococcus
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
CZ291047B6 (cs) * 1992-10-28 2002-12-11 Genentech, Inc. Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
WO1996025171A1 (en) * 1995-02-16 1996-08-22 F.Hoffmann-La Roche Ag Inhibition of angiogenesis using interleukin-12
WO1997041844A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
US5811403A (en) * 1996-09-30 1998-09-22 Vanderbilt University Polysaccharide toxin from Group B β-hemolytic Streptococcus (GBS) having improved purity
US6028060A (en) * 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin

Also Published As

Publication number Publication date
EP0981355A1 (de) 2000-03-01
HK1026372A1 (en) 2000-12-15
ES2205450T3 (es) 2004-05-01
WO1998032452A1 (en) 1998-07-30
CN1251997A (zh) 2000-05-03
CN1292759C (zh) 2007-01-03
EP0981355B1 (de) 2003-07-30
DE69816807D1 (de) 2003-09-04
DK0981355T3 (da) 2003-11-10
DE69816807T2 (de) 2004-04-15
AU6258898A (en) 1998-08-18
US6028060A (en) 2000-02-22
PT981355E (pt) 2003-12-31
JP2001509797A (ja) 2001-07-24
US6476002B1 (en) 2002-11-05

Similar Documents

Publication Publication Date Title
NO20013727L (no) Anvendelse av Botulinumtoksin B for fremstilling av et medikament
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
PT923293E (pt) Tratamento da diarreia
BG100960A (bg) Дозирани форми с контролирано освобождаване на азитромицин
FI943805A0 (fi) Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon
ES2168302T3 (es) Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
KR930009607A (ko) 증식성 질환의 치료를 위한 다이피리다몰
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE245991T1 (de) Behandlung chronischer entzündungskrankheiten mit cm101/gbs-toxin
DK0445280T3 (da) Terapeutisk middel og fremgangsmåde til inhibering af vaskularisering af tumorer
EA199800866A1 (ru) Способ снятия боли
IT1189298B (it) Procedimento per produrre i glicosa minoglicani dermatansolfato ed eparan-solfato sostanzialmente puri e loro impiego farmaceutico
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
AU4738500A (en) Improved method for treating mammals with modified mammalian blood
DK0814837T3 (da) Anvendelse af G-klasse-immunoglobuliner til topikal behandling af atopisk dermatitis
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
ATE149840T1 (de) Behandlung von leberkrebs
EA199800819A1 (ru) Способ лечения биполярного расстройства
PT1156795E (pt) Utilizacao de acido succinico ou de seus sais e metodo de tratamento da resistencia a insulina
AU1400895A (en) 2,3-diaryl-1-benzopyrans for treating dermatitis
EA199800822A1 (ru) Способ лечения избыточной агрессии
DE59305285D1 (de) Transdermales therapeutisches system mit pentylentetrazol als wirkstoff
EP0321094A3 (de) Behandlung von Faktor-VIII-Inhibitoren
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0981355

Country of ref document: EP

REN Ceased due to non-payment of the annual fee